Onconetix Inc (ONCO): Market Cap to Revenue Ratio

Corporate company logo of Onconetix Inc (ONCO)

The development of prostate cancer platforms is in its early stages, driving a linear increase in R&D expenses for Onconetix, Inc. (ONCO). A patent moat for biomarker tests in the US serves to protect its market share. Analyzing the price-to-sales ratio per share on GURU.Markets, we note that the 1.90 mark reflects the latest data, assisting management in commercializing innovations in urology.

ONCO Onconetix Corp: Price-to-Revenue Ratio in the range 04/13/2024 - 11/15/2026

Analytical breakdowns for Onconetix Inc (ONCO)

- current quotes and average value forecast:
Market Price Onconetix Inc|ONCO - Price Target Chart
- stock exchange capitalization data:
Market Capitalization Onconetix Corporation|ONCO - Enterprise Value
- business book valuation details:
Accounting Value per Share Onconetix|ONCO - Company Book Value|Market-to-Book Ratio onconetix.gcs-web.com|ONCO - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio Onconetix, Inc.|ONCO - Long-Term Debt to Capital|Current Liabilities to Capital Onconetix|ONCO - Company Total Debt|Debt to Book Capital Onconetix Corporation|ONCO - Company Long-Term Debts|Short-Term Debt Volume Onconetix|Immediate Liquidity Ratio onconetix.gcs-web.com
- business earnings and investment ratios data:
ONCO - Net Income|Expected Net Income Onconetix, Inc.|ONCO - P/E Multiple|Market Cap to Projected Earnings Onconetix Corporation|ONCO - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Onconetix Corporation|ONCO - Operating profit EBITDA|Net earnings per share for the last 12 months Onconetix|ONCO - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months onconetix.gcs-web.com|ONCO - Earnings per share growth in current year|Expected net earnings per share growth next year Onconetix, Inc.
- total revenue and sales volume data:
ONCO - Company Revenue|Company Revenue Forecast Onconetix|ONCO - P/S Multiple|Forward Price-to-Revenue Multiple Onconetix
Summary company analytics:Onconetix
Manufactured products of Onconetix

The P/S ratio determines the market value of one dollar of revenue, allowing an investor to assess the degree of an asset's overvaluation and timely identify a trend reversal. Analysis of the price-to-sales ratio reflects the monetization efficiency of R&D projects at Onconetix, Inc. (ONCO), linking the company's capitalization to the actual sales volume of its innovative diagnostic systems for combating prostate cancer.

Competing companies

Price-to-Revenue Ratio A (Agilent)|P/S Multiple DGX (questdiagnostics.com)|Illumina Platform - Price-to-Revenue Ratio|Exact Sciences Inc. - P/S Multiple|RVTY: Price-to-Revenue Ratio|Bio-Rad (BIO) - Price-to-Revenue Ratio|NNNN - Price-to-Revenue Coefficient|SHC (Sotera Health Corp) - P/S Multiple|Price to Sales QuidelOrtho Inc. QDEL|P/S Multiple OPK|CareDx - Market Cap to Revenue Ratio|P/S Multiple MRVI (Maravai LifeSciences Holdings)|Market Cap to Sales Volume FLGT (Fulgent Corp)|LAB: Market Cap to Revenue|Price-to-Revenue Coefficient Cytek Corp CTKB|OSUR (OraSure Technologies Inc) - Market Cap to Revenue|Market Cap to Revenue Exagen Inc.|Market Cap to Revenue MDXH|LUCD - Price-to-Revenue Multiple|Price-to-Revenue Ratio Prenetics (PRE)|Price-to-Revenue Ratio IMDX (Insight Molecular Diagnostics Inc)|Trinity Biotech - Market Cap to Revenue|prophaselabs.com - Price-to-Revenue Ratio|AIMD - Price-to-Revenue Ratio|Co-Diagnostics Inc (CODX) - Market Cap to Revenue|HSCS: P/S Multiple|BMRA - Price-to-Revenue Coefficient|Market Cap to Revenue CDIO|VRAX - Price-to-Revenue Multiple|Market Cap to Revenue BJDX (Bluejay Diagnostics)|P/S Multiple Aspira Women's Health, Inc. (AWH)|Price-to-Revenue Ratio acceleratediagnostics.com AXDX|Market Cap to Sales Volume CNTG (centogene.com)|ENZ - Price-to-Revenue Ratio|FRES - P/S Multiple|GENE: P/S Multiple|Market Cap to Revenue 23andMe|PMD (Psychemedics Corp.) - P/S Multiple